Table 1.
Correlations between GOLPH3 expression and clinicopathologic features in patients with pancreatic ductal adenocarcinoma (PDAC)
| Expression of GOLPH3 | ||||
|---|---|---|---|---|
| Clinicopathological feature | Total | Low (n = 30, 27.5%) | High (n = 79, 72.5%) | Pvalue (χ 2 test) |
| Age (years) | ||||
| <61 | 49 | 16 (32.7%) | 33 (67.3%) | 0.278 |
| ≥61 | 60 | 14 (23.3%) | 46 (76.7%) | |
| Gender | ||||
| Male | 68 | 18 (26.5%) | 50 (73.5%) | 0.751 |
| Female | 41 | 12 (29.3%) | 29 (70.7%) | |
| Tumor location | ||||
| Head | 87 | 25 (28.7%) | 62 (71.3%) | 0.573 |
| Body/tail | 22 | 5 (22.7%) | 17 (77.3%) | |
| Clinical stage (pTNM) | ||||
| I | 15 | 7 (46.7%) | 8 (53.3%) | 0.006* |
| II | 50 | 6 (12.0%) | 44 (88.0%) | |
| III | 22 | 7 (31.8%) | 15 (68.2%) | |
| IV | 22 | 10 (45.5%) | 12 (54.5%) | |
| Histological differentiation | ||||
| Well | 7 | 2 (28.6%) | 5 (71.4%) | 0.949 |
| Moderate/poor | 102 | 28 (27.5%) | 74 (72.5%) | |
| Size | ||||
| ≤2 cm | 17 | 7 (41.2%) | 10 (58.8%) | 0.170 |
| >2 cm | 92 | 23 (25.0%) | 69 (75.0%) | |
| T classification | ||||
| T1 | 5 | 2 (40.0%) | 3 (60.0%) | 0.021* |
| T2 | 25 | 10 (40.0%) | 15 (60.0%) | |
| T3 | 48 | 6 (12.5%) | 42 (87.5%) | |
| T4 | 31 | 12 (38.7%) | 19 (61.3%) | |
| N classification | ||||
| Absent | 56 | 20 (35.7%) | 36 (64.3%) | 0.049* |
| Present | 53 | 10 (18.9%) | 43 (81.1%) | |
| Liver metastasis | ||||
| Absent | 87 | 20 (22.7%) | 67 (77.3%) | 0.035* |
| Present | 22 | 10 (47.6%) | 12 (52.4%) | |
| Resectability | ||||
| Radical resection | 69 | 19 (27.5%) | 50 (72.5%) | 0.997 |
| Palliative resection | 40 | 11 (27.5%) | 29 (72.5%) | |
| Vital status | ||||
| Dead | 97 | 27 (27.8%) | 70 (72.2%) | 0.836 |
| Alive | 12 | 3 (25.0%) | 9 (75.0%) | |
*Statistically significant; pTNM: tumor-node-metastasis classification pancreatic cancer staging.